ADVR scientists will be working with the Department of Chemistry and Chemical Biology to identify how compounds such as AVR118, a Phase II clinical candidate, interact with clinically relevant molecular targets associated with cancer.
Another important goal of this agreement is to apply ADVR’s innovative AFP technology to identify new compounds with anti-cancer activity. In combination with Northeastern’s Mass Spectrometry (MS) and Nuclear Magnetic Resonance (NMR) analytical capabilities, the AFP technology is expected to improve the efficiency of discovering new lead compounds.